Posted by Michael Wonder on 30 Oct 2017
Merck provides update on European application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin for first-line treatment of non-squamous non-small cell lung cancer
27 October 2017 - Merck today announced that it has withdrawn its European application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as a first-line treatment for metastatic non-squamous non-small-cell lung cancer.
The application was based on findings from KEYNOTE-021, Cohort G. Merck is confident in the clinical data from this rigorously conducted trial, which demonstrated significant improvements in overall response rate and progression-free survival for the Keytruda combination regimen compared to chemotherapy alone.
Additionally, the company’s broad clinical development program includes a number of studies evaluating Keytruda in combination with chemotherapy in the first-line non-small-cell lung cancer setting. Merck looks forward to sharing data from these studies with regulatory authorities and the medical community as they become available.
